Veritas Asset Management LLP Makes New $175.32 Million Investment in Waters Corporation $WAT

Veritas Asset Management LLP purchased a new position in shares of Waters Corporation (NYSE:WAT) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 584,770 shares of the medical instruments supplier’s stock, valued at approximately $175,320,000. Waters accounts for about 1.9% of Veritas Asset Management LLP’s investment portfolio, making the stock its 16th biggest holding.

Several other institutional investors and hedge funds have also modified their holdings of the business. Integrated Wealth Concepts LLC raised its holdings in Waters by 2.9% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after buying an additional 30 shares during the period. Exchange Traded Concepts LLC increased its position in shares of Waters by 5.9% during the third quarter. Exchange Traded Concepts LLC now owns 630 shares of the medical instruments supplier’s stock worth $189,000 after acquiring an additional 35 shares in the last quarter. Penserra Capital Management LLC raised its holdings in shares of Waters by 13.1% during the second quarter. Penserra Capital Management LLC now owns 327 shares of the medical instruments supplier’s stock worth $114,000 after acquiring an additional 38 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its position in Waters by 1.8% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,264 shares of the medical instruments supplier’s stock valued at $679,000 after acquiring an additional 41 shares in the last quarter. Finally, CW Advisors LLC boosted its stake in Waters by 2.0% in the 2nd quarter. CW Advisors LLC now owns 2,112 shares of the medical instruments supplier’s stock worth $737,000 after purchasing an additional 42 shares during the period. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

WAT has been the topic of several recent research reports. Wells Fargo & Company lifted their price target on Waters from $385.00 to $415.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Hsbc Global Res raised Waters to a “strong-buy” rating in a research report on Tuesday, January 27th. Rothschild & Co Redburn initiated coverage on Waters in a research note on Wednesday, October 8th. They issued a “buy” rating and a $390.00 target price on the stock. TD Cowen reaffirmed a “hold” rating on shares of Waters in a research report on Wednesday, November 5th. Finally, Morgan Stanley initiated coverage on shares of Waters in a report on Monday, December 1st. They issued an “equal weight” rating and a $423.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $398.61.

Waters Stock Down 1.3%

NYSE:WAT opened at $370.47 on Monday. Waters Corporation has a twelve month low of $275.05 and a twelve month high of $423.00. The firm has a market capitalization of $22.06 billion, a price-to-earnings ratio of 34.05, a price-to-earnings-growth ratio of 3.10 and a beta of 1.18. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The stock’s 50 day moving average price is $390.42 and its two-hundred day moving average price is $344.13.

Waters (NYSE:WAT) last released its earnings results on Tuesday, November 4th. The medical instruments supplier reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.21 by $0.19. The business had revenue of $799.89 million during the quarter, compared to analysts’ expectations of $780.05 million. Waters had a net margin of 20.89% and a return on equity of 36.59%. The firm’s revenue was up 8.1% on a year-over-year basis. During the same period last year, the business earned $2.93 earnings per share. Waters has set its FY 2025 guidance at 13.050-13.150 EPS and its Q4 2025 guidance at 4.450-4.550 EPS. Equities research analysts expect that Waters Corporation will post 12.86 earnings per share for the current fiscal year.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.